FindTrial
Sign In

Growth Hormone in EB

Assessment of Growth Hormone and Insulin-like Growth Factor 1 in Children With Epidermolysis Bullosa Dystrophia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05390073
Enrollment
50
Registered
2022-05-25
Start date
2022-05-25
Completion date
2022-06-15
Last updated
2022-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidermolysis Bullosa Dystrophica

Brief summary

Growth is extremely affected in epidermolysis bullosa patients

Detailed description

Studying the role of growth hormone and ILGF-1 in EB may pave the to new therapeutic modality that could improve the growth in those children and avoid the irreversible sequelae that affected subjects experience after adulthood

Interventions

DIAGNOSTIC_TESTgrowth hormone level and insulin like growth factor 1

laboratory test

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
1 Months to 12 Years

Inclusion criteria

\- Children with EB dystrophica

Exclusion criteria

* Adults with the same disease

Design outcomes

Primary

MeasureTime frameDescription
level of growth hormone and insulin like growth factor 12 weekslaboratory test

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026